Abstract | BACKGROUND AND AIM: METHODS AND RESULTS: A multicenter, randomized, double-blind, double-dummy, parallel group study was designed to evaluate the effect of 3 months' treatment with atorvastatin (10mg/day) or pravastatin (20mg/day) on the lipid/ lipoprotein profile and LDL size in a total of 86 FCHL patients. Both statins significantly lowered plasma total and LDL cholesterol, with a significantly higher hypocholesterolemic effect observed with atorvastatin (-26.8+/-11.1% and -35.9+/-11.1%, respectively) compared to pravastatin (-17.6+/-11.1% and -24.5+/-10.2%). The percent decrease in plasma triglycerides was highly variable, but more pronounced with atorvastatin (-19.8+/-29.2%) than with pravastatin (-5.3+/-48.6%). Opposite changes in LDL size were seen with the 2 treatments, with increased mean LDL particle diameter with atorvastatin, and decreased diameter with pravastatin, and significant between treatment difference in terms of percent modification vs baseline (+0.5+/-1.6% with atorvastatin vs -0.3+/-1.8% with pravastatin). CONCLUSIONS: The present results support the evidence indicative of a greater hypocholesterolemic effect of atorvastatin compared to pravastatin, and in addition show a raising effect of atorvastatin on the size of LDL particles in FCHL patients.
|
Authors | Cesare R Sirtori, Laura Calabresi, Livia Pisciotta, Luigi Cattin, Paolo Pauciullo, Mario Montagnani, Enzo Manzato, Gabriele Bittolo Bon, Renato Fellin |
Journal | Nutrition, metabolism, and cardiovascular diseases : NMCD
(Nutr Metab Cardiovasc Dis)
Vol. 15
Issue 1
Pg. 47-55
(Feb 2005)
ISSN: 0939-4753 [Print] Netherlands |
PMID | 15871851
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Anticholesteremic Agents
- Cholesterol, LDL
- Heptanoic Acids
- Pyrroles
- Triglycerides
- Atorvastatin
- Pravastatin
|
Topics |
- Anticholesteremic Agents
(therapeutic use)
- Atorvastatin
- Cholesterol, LDL
(blood, drug effects)
- Double-Blind Method
- Female
- Heptanoic Acids
(therapeutic use)
- Humans
- Hyperlipidemia, Familial Combined
(drug therapy)
- Male
- Middle Aged
- Particle Size
- Pravastatin
(therapeutic use)
- Pyrroles
(therapeutic use)
- Treatment Outcome
- Triglycerides
(blood)
|